- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01413763
Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis
A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a double-blind, randomized, placebo-controlled, 2-way crossover study designed to assess the potential effect of topically applied 3.75% imiquimod cream on atrial ectopy in actinic keratosis (AK) patients. Candidates for study participation will begin screening procedures up to 28 days prior to enrollment. Qualified subjects shall be admitted to the CRU on Day -1 for baseline evaluations and will be randomized to one of two possible treatment sequences. Each subject will receive both the active 3.75% imiquimod cream and the matching placebo in a randomized crossover fashion with a 2-week washout in between each treatment. The application area is the entire face (exclusive of nares, vermilion, periocular areas and ears) or balding scalp. Atrial ectopy will be monitored for 24 hours at Baseline (Day -1; prior to the first dose of study medication), and at the conclusion of each 14-day treatment period using a continuous 12-lead digital Holter recorder.
Adverse events, concomitant medication use, study medication accountability, and subject compliance will be reviewed at each visit.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Florida
-
Fort Meyers, Florida, United States, 33901
- Comprehensive Phase One
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female AK patients with at least 5 typical visible or palpable AK lesions on face or balding scalp
- AK patients in otherwise good general health age 18 years and above
- Female subjects of childbearing potential must be non-pregnant and non-lactating
Exclusion Criteria:
- Previous clinical study participation within 30 days (drug or device)
- Evidence of clinically significant diseases
- History of drug or alcohol abuse
- Subjects with uncontrolled systemic hypertension, NYHA heart failure classification Class > II, or a history of atrial fibrillation or atrial flutter
- Subjects using imiquimod or interferon within 30 days prior to the first dose of study medication
- Have known allergies to any excipient in the study cream
- Have melanoma anywhere on the body
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Imiquimod cream
|
3.75% cream, applied daily for 2 weeks
|
Placebo Comparator: Placebo cream
|
placebo cream applied daily for 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in 24-hour supraventricular beat count
Time Frame: Day 14 of each treatment period
|
Day 14 of each treatment period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in 24-hour supraventricular premature couplet and run counts and atrial fibrillation (% time)
Time Frame: Day 14 of each treatment period
|
Day 14 of each treatment period
|
Change in 24-hour mean heart rate
Time Frame: Day 14 of each treatment period
|
Day 14 of each treatment period
|
Change in 24-hour ventricular premature beat count, ventricular premature couplet and run counts
Time Frame: Day 14 of each treatment period
|
Day 14 of each treatment period
|
Collaborators and Investigators
Investigators
- Study Director: Robert W Babilon, MS, MBA, Graceway Pharmaceuticals, LLC
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GW01-1001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratosis
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
Clinical Trials on Imiquimod cream 3.75%
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
Taro Pharmaceuticals USACompleted
-
Actavis Mid-Atlantic LLCCompleted
-
Teva Pharmaceuticals USACompletedActinic KeratosisUnited States
-
Icahn School of Medicine at Mount SinaiBausch Health Americas, Inc.CompletedActinic KeratosisUnited States
-
Rochester General HospitalBausch Health Americas, Inc.; Rochester Skin Lymphoma Medical Group, PLLCWithdrawn
-
Medical University of GrazCompleted
-
Graceway Pharmaceuticals, LLCCompletedActinic KeratosisUnited States
-
Graceway Pharmaceuticals, LLCCompletedKeratosisUnited States